Corrections:

Joshua E. Allen¹, C. Leah B. Kline², Varun V. Prabhu¹, Jessica Wagner², Jo Ishizawa³, Neel Madhukar⁴, Avital Lev², Marie Baumeister², Lanlan Zhou², Amriti Lulla², Martin Stogniew¹, Lee Schalop¹, Cyril Benes^5,6, Howard L. Kaufman⁷, Richard S. Pottorf⁸, B. Rao Nallaganchu⁸, Gary L. Olson⁸, Fahd Al-Mulla⁹, Madeleine Duvic³, Gen Sheng Wu¹⁰, David T. Dicker², Mala K. Talekar¹¹, Bora Lim³, Olivier Elemento⁴, Wolfgang Oster¹, Joseph Bertino⁷, Keith Flaherty^5,6, Michael L. Wang³, Gautam Borthakur³, Michael Andreeff³, Mark Stein⁷ and Wafik S. El-Deiry²

¹ Oncoceutics, Inc., Philadelphia, PA, USA
² Fox Chase Cancer Center, Philadelphia, PA, USA
³ University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁴ Weill Cornell Medicine, New York, NY, USA
⁶ Harvard Medical School, Boston, MA, USA
⁷ Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
⁸ Provid Pharmaceuticals, Monmouth Junction, NJ, USA
⁹ Kuwait University Medical School, Kuwait
¹⁰ Karmanos Cancer Institute, Detroit, MI, USA
¹¹ The Children’s Hospital of Philadelphia, Philadelphia, PA, USA

Published: October 12, 2021

Copyright: © 2021 Allen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The COI statement has been updated. Please see the revised text below:

CONFLICTS OF INTEREST

W.S.E-D. is a co-founder and shareholder of Oncoceutics, Inc. W.S.E-D. is fully compliant with institutional disclosure requirements and conflict of interest rules. Dr. Michael Andreeff is also a shareholder of Oncoceutics, Inc. Some of the additional authors are employees or shareholders at Oncoceutics, Inc.

Original article: Oncotarget. 2016; 7:74380–74392. DOI: https://doi.org/10.18632/oncotarget.11814